Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Epirubicin

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Epirubicin: Observational Study

Pfizer CT.gov Call Center

Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events.

(E=Epirubicin; C =Cyclophosphamide)

Postmarketing surveillance study. Non-Probability Sample

Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer

Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))

Percentage of participants with DFS who completed 5 year follow-up visit.

Pfizer

Director, Clinical Trial Disclosure Group

Only spontaneous adverse events were collected as reported by health care professionals. All events are reported under serious adverse events.

Includes groups enrolled to receive all treatments of epirubicin

Includes all groups enrolled in the study

Entire Study Population

Age Continuous

>=20 and <30 years

>=30 and <40 years

>=40 and <50 years

>=50 and <60 years

>=60 and <70 years

>=70 and <80 years

>=80 and <90 years

Unknown

Age, Customized

Sex: Female, Male

Pfizer ClinicalTrials.gov Call Center

Percentage of Participants With Disease Free Survival (DFS)

16.3% of patients had experienced disease progression by the end of the study. As this is less than 50% the median time to progression is not defined.

Time to Progression (TTP)

Median time to recurrence was not reached.

Time to Recurrence (DFI)

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer	NCT01061359	Breast Neoplasm	Epirubicin: Obs...	-	Pfizer
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer	NCT01061359	Breast Neoplasm	Epirubicin: Obs...	-	Pfizer

Spots Global Cancer Trial Database for epirubicin: observational study